Bayer, NextRNA Therapeutics to Collaborate on New Class of Tumor Treatment
By Pierre Bertrand
Bayer and U.S. biotechnology company NextRNA Therapeutics agreed to collaborate on the development of small molecules to be used in the treatment of tumors.
NextRNA, based in Boston, is to get up to $547 million for the development of two small-molecule programs, the companies said.
They aim for the molecules to serve as a new class of therapeutic agents disrupting a key driver in the growth of tumors, the companies said.
Bayer and NextRNA will work together on a first program already in early preclinical development. In the second, Bayer will have the option to select one target for joint development.
Included in the agreement's funds are upfront and near-term milestone payments, development and commercial milestone payments, research funding as well as tiered royalties on net sales, according to the companies.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
August 28, 2024 07:14 ET (11:14 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks
United States